Cure8 research brief
Because having a sibling with Crohn's disease during childhood was linked to substantially higher risk of developing Crohn's later, and the study points to early-life microbiome differences and elevated faecal calprotectin as potential markers of higher risk.
Researchers studying IBD risk and microbiome, clinicians who follow relatives of people with Crohn's, and parents/caregivers of children with an affected sibling.
This paper used prospective cohort data (GEM) and a nationwide South Korean dataset to show childhood exposure to an affected sibling was associated with a higher adjusted hazard of Crohn's onset compared with adult exposure.
The GEM cohort also showed reduced abundances of specific gut bacteria (Lachnospira, Roseburia, Colidextribacter) in childhood-exposed siblings; mediation analysis and mouse transfer experiments supported a potential causal role for the microbiota.
The authors trained a risk model combining faecal calprotectin and microbial enterotypes that identified a subgroup with higher 10-year incidence.
What this does not mean: This is an observational and translational study that identifies associations and experimental signals in mice; it does not prove that changing the microbiome will prevent Crohn's in humans. Clinical decisions about monitoring or prevention should be made with a clinician.
Structured content depth: abstract — the supplied text is an abstract and summary from the journal Gut. The findings combine cohort analysis, microbiome profiling, mouse transfer experiments, and an internally validated risk model; as an abstract, full methods and limitations are in the full paper.
Observational associations and animal-model results do not by themselves establish effective preventive interventions.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If fecal GP2 reliably reflects UC activity and microbial changes, it could become a noninvasive marker to track inflammation or to study disease mechanisms that differ between UC and CD.
This model aims to identify healthy first‑degree relatives at higher risk of developing Crohn’s disease before symptoms start, which could enable earlier monitoring or preventive strategies. The score uses simple...
Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.
